Mechanisms of human neutrophil elastase-catalysed inactivation of factor VIII(a)

Summary

Mechanisms of inflammation and coagulation are linked through various pathways. Human neutrophil elastase (HNE), can bind to activated platelets, might be localised on platelet membranes that provide negatively-charged phospholipid essential for the optimum function of tenase complex. In this study, we examined the effect of HNE on factor (F)VIII. FVIII activity was rapidly diminished in the presence of HNE and was undetectable within 10 minutes. The inactivation rate waŝ8-fold greater than that of activated protein C (APC). This time-dependent inactivation was moderately affected by von Willebrand factor. HNE proteolysed the heavy chain (HCh) of FVIII into two terminal products, A1^1–358 and A2^375–708, by limited proteolysis at Val³⁵⁸, Val³⁷⁴, and Val⁷⁰⁸. Cleavage at Val⁷⁰⁸ was much slower than that at Val³⁵⁸ in the >90-kDa A1-A2-B compared to the 90-kDa A1-A2. The 80-kDa light chain (LCh) was proteolysed to 75-kDa product by cleavage at Val¹⁶⁷⁰. HNE-cata- lysed FVIIIa inactivation was markedly slower than that of native FVIII (by ~25-fold), due to delayed cleavage at Val⁷⁰⁸ in FVIIIa. The inactivation rate mediated by HNE was ~8-fold lower than that by APC. Cleavages at Val³⁵⁸ and Val⁷⁰⁸ were regulated by the presence of LCh and HCh, respectively. In conclusion, HNE-catalysed FVIII inactivation was associated with the limited-proteolysis that led to A1^1–358, A2^375–708, and A3-C1-C2^1671–2332, and subsequently to critical cleavage at Val⁷⁰⁸. HNE-related FVIII(a) reaction might play a role in inactivation of HNE-induced coagulation process, and appeared to depend on the amounts of inactivated FVIII and active FVIIIa which is predominantly resistant to HNE inactivation.

Note: An account of this work was presented at the 51st annual meeting of the American Society of Hematology, December 10, 2009, New Orleans, LA, USA.

Keywords

FVIII - FVIIIa - human neutrophil elastase (HNE) - inactivation - proteolysis

• References

• 1 Mann KG, Nesheim ME, Church WR. et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
• 2 Hoyer LW. The factor VIII complex: structure and function. Blood 1981; 58: 1-13.
• 3 Wood WI, Capon DJ, Simonsen CC. et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337.
• 4 Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
• 5 Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
• 6 Fay PJ, Mastri M, Koszelak ME. et al. Cleavage of factor VIII heavy chain is required for the functional interaction of A2 subunit with factor IXa. J Biol Chem 2001; 276: 12434-12439.
• 7 Regan LM, Fay PJ. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem 1995; 270: 8546-8552.
• 8 Nogami K, Shima M, Matsumoto T. et al. Mechanisms of plasmin-catalyzed inactivation of factor VIII: a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation. J Biol Chem 2007; 282: 5287-5295.
• 9 Nogami K, Wakabayashi H, Schmidt K. et al. Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa. J Biol Chem 2003; 278: 1634-1641.
• 10 Nogami K, Freas J, Manithody C. et al. Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain. J Biol Chem 2004; 279: 33104-33113.
• 11 Regan LM, Lamphear BJ, Huggins CF. et al. Factor IXa protects factor VIIIa from activated protein C. Factor IXa inhibits activated protein C-catalyzed cleavage of factor VIIIa at Arg562. J Biol Chem 1994; 269: 9445-9452.
• 12 Watorek W, Farley D, Salvesen G. et al. Neutrophil elastase and cathepsin G: structure, function, and biological control. Adv Exp Med Biol 1988; 240: 23-31.
• 13 Campbell EJ, Senior RM, Welgus HG. Extracellular matrix injury during lung inflammation. Chest 1987; 92: 161-167.
• 14 Sifers RN, Shen RM, Woo SLC. Genetic control of human alpha-1-antitrypsin. Mol Bio Med 1989; 6: 127-135.
• 15 Travis J. Structure, function, and control of neutrophil proteinases. Am J Med 1988; 84: 37-42.
• 16 Bach-Gansmo ET, Halvorsen S, Godal HC. et al. Impaired coagulation of fibrinogen due to digestion of the C-terminal end of the A alpha-chain by human neutrophil elastase. Thromb Res 1994; 73: 61-68.
• 17 Samis JA, Garrett M, Manuel RP. et al. Human neutrophil elastase activates human factor V but inactivates thrombin-activated human factor V. Blood 1997; 90: 1065-1074.
• 18 Varadi K, Marossy K, Asboth G. et al. Inactivation of human factor VIII by granulocyte proteases. Thromb Haemost 1980; 43: 45-52.
• 19 Takaki A, Enfield DL, Thompson AR. Cleavage and inactivation of factor IX by granulocyte elastase. J Clin Invest 1983; 72: 1706-1715.
• 20 Turkington PT. Degradation of human factor X by human polymorphonuclear leucocyte cathepsin G and elastase. Haemostasis 1991; 21: 111-116.
• 21 Eckle I, Seitz R, Egbring R. et al. Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler 1991; 372: 1007-1013.
• 22 Eckle I, Seitz R, Egbring R. et al. Protein S degradation in vitro by neutrophil elastase. Scand J Clin Lab Invest 1993; 53: 281-288.
• 23 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
• 24 Shima M, Yoshioka A, Nakajima M. et al. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells. Br J Haematol 1992; 81: 533-538.
• 25 O’Brien LM, Huggins CF, Fay PJ. Interacting regions in the A1 and A2 subunits of factor VIIIa identified by zero-length cross-linking. Blood 1997; 90: 3943-3950.
• 26 Foster PA, Fulcher CA, Houghten RA. et al. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest 1988; 82: 123-128.
• 27 Mimms LT, Zampighi G, Nozaki Y. et al. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-840.
• 28 Lollar P, Fay PJ, Fass DN. Factor VIII and factor VIIIa. Methods Enzymol 1993; 222: 128-143.
• 29 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
• 30 Curtis JE, Helgerson SL, Parker ET. et al. Isolation and characterization of thrombin-activated human factor VIII. J Biol Chem 1994; 269: 6246-6251.
• 31 Jenkins PV, Dill JL, Zhou Q. et al. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry 2004; 43: 5094-5101.
• 32 Owen CA, Campbell MA, Sannes PL. et al. Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 1995; 131: 775-789.
• 33 Nagamatsu Y, Yamamoto J, Fukuda A. et al. Determination of leukocyte elastase concentration in plasma and serum by a simple method using a specific synthetic substrate. Haemostasis 1991; 21: 338-345.
• 34 Shen BW, Spiegel PC, Chang CH. et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111: 1240-1247.
• 35 Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res 1998; 26: 216-219.
• 36 Jenkins PV, Dill JL, Zhou Q. et al. Clustered basic residues within segment 484–510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation. J Thromb Haemost 2004; 2: 452-458.
• 37 Jagannathan I, Ichikawa HT, Kruger T. et al. Identification of residues in the 558-loop of factor VIIIa A2 subunit that interact with factor IXa. J Biol Chem 2009; 284: 32248-32255.
• 38 Lenting PJ, van de Loo JW, Donath MJ. et al. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996; 271: 1935-1940.
• 39 Soeda T, Nogami K, Nishiya K. et al. The factor VIIIa C2 domain (residues 2228–2240) interacts with the factor IXa Gla domain in the factor Xase complex. J Biol Chem 2009; 284: 3379-3388.
• 40 Koedam JA, Hamer RJ, Beeser-Visser NH. et al. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem 1990; 189: 229-234.
• 41 Fay PJ, Coumans JV, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266: 2172-2177.
• 42 Andersson LO, Brown JE. Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J 1981; 200: 161-167.
• 43 Nogami K, Shima M, Nishiya K. et al. A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation. Blood 2002; 99: 3993-3998.
• 44 Raife TJ, Cao W, Atkinson BS. et al. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114: 1666-1674.
• 45 Church WR, Jernigan RL, Toole J. et al. Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. Proc Natl Acad Sci USA 1984; 81: 6934-6937.
• 46 Massberg S, Grahl L, von Bruehl ML. et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887-896.